Thus, it was shown that therapies aiming to reactivate the RB pathway may have tumor suppressive effects, not through a suppression of cell proliferation, but inducing the reversion of cell state changes associated with advanced tumor progression and related to RB1 deficiency [690]. Here, RB1 is linked to neoplasm.